XASX
HLS
Market cap202mUSD
Oct 09, Last price
0.39AUD
1D
-2.50%
1Q
1.30%
Jan 2017
-90.09%
Name
Healius Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services. The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services. Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures. These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers. Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
Key people
Kathryn McKenzie
Interim Non-Executive Independent Chairman of the Board · since 2023
Puneet Nagi
Chief Operating Officer · since 2025
Kylie Brown
Chief Risk Officer, Group General Counsel, Joint Company Secretary · since 2025
Prasad Arav
Group Executive - Digital and Technology and Strategy · since 2021
Paula Bayliss
Group Executive - People & Culture · since 2024
Phil Lucas
Group Executive - Lumus Imaging · since 2023
Anthea Muir
Group Executive, Customer & Commercial · since 2025
Rodney Rudling
Group Executive, Clinical Integration · since 2024
Andrew Thomson
Chief Financial Officer, Joint Company Secretary · since 2025
Paul Anderson
Chief Executive Officer, Managing Director, Director · since 2024
Christopher Hall
Non-Executive Director · since 2025
Non-Executive Director · since 2023
Neil Vinson
Non-Executive Director · since 2025
Non-Executive Independent Director · since 2018
John Mattick
Non-Executive Independent Director · since 2022
Katherine Ostin
Non-Executive Independent Director · since 2024
Charles Taylor
Non-Executive Independent Director · since 2023
Headquarters & legal address
c/o IDAMENEO (NO. 789) LIMITED, Level 6, 203 Pacific Highway
St Leonards, NSW 2065
AU
St Leonards, NSW 2065
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||